<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1098</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>12456667</PubmedId>
            <Abstract>AZT (3'-azido-3'-deoxythymidine) resistance involves the enhanced excision of AZTMP from the end of the primer strand by HIV-1 reverse transcriptase. This reaction can occur when an AZTMP-terminated primer is bound at the nucleotide-binding site (pre-translocation complex N) but not at the 'priming' site (post-translocation complex P). We determined the crystal structures of N and P complexes at 3.0 and 3.1 A resolution. These structures provide insight into the structural basis of AZTMP excision and the mechanism of translocation. Docking of a dNTP in the P complex structure suggests steric crowding in forming a stable ternary complex that should increase the relative amount of the N complex, which is the substrate for excision. Structural differences between complexes N and P suggest that the conserved YMDD loop is involved in translocation, acting as a springboard that helps to propel the primer terminus from the N to the P site after dNMP incorporation.</Abstract>
            <ArticleYear>2002</ArticleYear>
            <ArticlePages>6614-24</ArticlePages>
            <ArticleTitle>Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNA.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Sarafianos</LastName>
                    <ForeName>Stefan G</ForeName>
                </Author>
                <Author>
                    <LastName>Clark</LastName>
                    <ForeName>Arthur D</ForeName>
                    <Suffix>Jr</Suffix>
                </Author>
                <Author>
                    <LastName>Das</LastName>
                    <ForeName>Kalyan</ForeName>
                </Author>
                <Author>
                    <LastName>Tuske</LastName>
                    <ForeName>Steve</ForeName>
                </Author>
                <Author>
                    <LastName>Birktoft</LastName>
                    <ForeName>Jens J</ForeName>
                </Author>
                <Author>
                    <LastName>Ilankumaran</LastName>
                    <ForeName>Palanichamy</ForeName>
                </Author>
                <Author>
                    <LastName>Ramesha</LastName>
                    <ForeName>Andagar R</ForeName>
                </Author>
                <Author>
                    <LastName>Sayer</LastName>
                    <ForeName>Jane M</ForeName>
                </Author>
                <Author>
                    <LastName>Jerina</LastName>
                    <ForeName>Donald M</ForeName>
                </Author>
                <Author>
                    <LastName>Boyer</LastName>
                    <ForeName>Paul L</ForeName>
                </Author>
                <Author>
                    <LastName>Hughes</LastName>
                    <ForeName>Stephen H</ForeName>
                </Author>
                <Author>
                    <LastName>Arnold</LastName>
                    <ForeName>Eddy</ForeName>
                </Author>
            </Authors>
            <Affiliations>Center for Advanced Biotechnology and Medicine, 679 Hoes Lane, Piscataway, NJ 08854-5638, USA.</Affiliations>
            <ArticleChemicalList>Dideoxynucleotides;Thymine Nucleotides;3'-azido-3'-deoxythymidine 5'phosphate;Zidovudine;DNA;RNA-Directed DNA Polymerase</ArticleChemicalList>
            <ArticleMeshHeadingsList>DNA(biosynthesis; metabolism); Dideoxynucleotides; Drug Resistance, Viral(physiology); HIV-1(metabolism); Humans; RNA-Directed DNA Polymerase(metabolism); Thymine Nucleotides(metabolism); Zidovudine(analogs &amp; derivatives; metabolism)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>21</Volume>
                <Issue>23</Issue>
                <Title>The EMBO journal</Title>
                <Issn>0261-4189</Issn>
                <MedlineTa>EMBO J</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>Epitope of Fab28 on HIV-1 RT</EpitopeName>
                <EpitopeStructure>
                    <DiscontinuousRegionOnAccessionSequenceMolecule>
                        <ChemicalType>Discontinuous protein residues</ChemicalType>
                        <DiscontinuousResidues>R199, Q222, K223, E224, P225, P226, F227, W229, M230, R358</DiscontinuousResidues>
                        <SourceMolecule>
                            <GenBankId>NP_789739.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11676</SourceOrganismId>
                    </DiscontinuousRegionOnAccessionSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>PDB 1N6Q and 1N5Y</LocationOfData>
                <EpitopeId>150096</EpitopeId>
                <ReferenceRegion>B: R199, Q222, K223, E224, P225, P226, F227, W229, M230, R358</ReferenceRegion>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>The epitope residues are calculated from the PDB structure [PDB: 1N6Q] as the antigen residues at 4 Ã… distance from the antibody.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1 and PDB 1N6Q</LocationOfData>
                        <BCellId>1842148</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Age>8 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>NP_789739.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>11676</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>HIV-1 RT (66 kDa form)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>2 doses at a 2-wk interval and 1 dose 4 days before cell fusion</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Generation of the monoclonal antibody was previously described in the reference: Ferris et al. (1990) Virology 175(2): 456-464 [PMID: 1691562]. Mice were immunized with purified RT (66 kDa form).</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>436</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>3.0</QuantitativeMeasurement>
                            <MeasurementInequality>=</MeasurementInequality>
                            <AssayComments>The epitope of Fab28 on the HIV-1 RT p51 subunit was determined from the crystal structure of Fab28 bound to the complex of HIV-1 RT p51/p66 dimer cross-linked to AZTMP-terminated DNA template-primer (27-mer/22-mer) (Complex N). Fab28 binds to the p51 palm subdomain and has no contacts with either the p66 subunit or the dsDNA. The RT p51 subunit contained the C280C mutation and a C-terminal 2 Gly and 7 His tail.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Fab</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>28</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                            <AssayedAntibodyObject>
                                <MultiChainMolecule>
                                    <ChemicalType>Multi-Chain protein</ChemicalType>
                                    <MoleculeName>Fab28</MoleculeName>
                                    <Chain1>
                                        <Molecule>
                                            <GenBankId>1T03_H</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10090</SourceOrganismId>
                                    </Chain1>
                                    <Chain2>
                                        <Molecule>
                                            <GenBankId>1T03_L</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10090</SourceOrganismId>
                                    </Chain2>
                                </MultiChainMolecule>
                            </AssayedAntibodyObject>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>HIV-1 RT p51/p66 dimer/DNA</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>NP_789739.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>11676</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <ComplexedMolecule>
                                    <ComplexType>Protein conjugate</ComplexType>
                                    <PeptideModifications/>
                                    <SourceMolecule>
                                        <GenBankId>YP_001856242.1</GenBankId>
                                    </SourceMolecule>
                                    <MoleculeSourceOrganismId>11676</MoleculeSourceOrganismId>
                                </ComplexedMolecule>
                            </AntigenContainingObject>
                        </Antigen>
                        <ThreeDimensionalStructureOfComplex>
                            <ComplexPdbId>1N6Q</ComplexPdbId>
                            <AntibodyChain1PdbChain>H</AntibodyChain1PdbChain>
                            <AntibodyChain2PdbChain>L</AntibodyChain2PdbChain>
                            <AntigenChainPdbChain>B</AntigenChainPdbChain>
                            <ViewerFlag>Y</ViewerFlag>
                            <CuratedContacts>
                                <EpitopeResidues>B: ;</EpitopeResidues>
                                <AntibodyResiduesInteractingWithAntigen>H: ; L: ;</AntibodyResiduesInteractingWithAntigen>
                            </CuratedContacts>
                            <CalculatedContacts>
                                <EpitopeResidues>B: R199, Q222, K223, E224, P225, P226, F227, W229, M230, R358</EpitopeResidues>
                                <AntibodyResiduesInteractingWithAntigen>H: S32, W54, W55, D56, D58, R60, I102, T103, S104, V105, T106, S108; L: Y32, Y91, S92, K93, F94</AntibodyResiduesInteractingWithAntigen>
                                <ContactAreaForAntigen>707.5</ContactAreaForAntigen>
                                <ContactAreaForAntibody>642.8</ContactAreaForAntibody>
                            </CalculatedContacts>
                        </ThreeDimensionalStructureOfComplex>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1 and PDB 1N5Y</LocationOfData>
                        <BCellId>1842151</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Age>8 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>NP_789739.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>11676</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>HIV-1 RT (66 kDa form)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>2 doses at a 2-wk interval and 1 dose 4 days before cell fusion</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Generation of the monoclonal antibody was previously described in the reference: Ferris et al. (1990) Virology 175(2): 456-464 [PMID: 1691562]. Mice were immunized with purified RT (66 kDa form).</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>436</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>3.1</QuantitativeMeasurement>
                            <MeasurementInequality>=</MeasurementInequality>
                            <AssayComments>The epitope of Fab28 on the HIV-1 RT p51 subunit was determined from the crystal structure of Fab28 bound to the complex of HIV-1 RT p51/p66 dimer cross-linked to AZTMP-terminated DNA template-primer (27-mer/21-mer) (Complex P). Fab28 binds to the p51 palm subdomain and has no contacts with either the p66 subunit or the dsDNA. The RT p51 subunit contained the C280C mutation and a C-terminal 2 Gly and 7 His tail.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Fab</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>28</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                            <AssayedAntibodyObject>
                                <MultiChainMolecule>
                                    <ChemicalType>Multi-Chain protein</ChemicalType>
                                    <MoleculeName>Fab28</MoleculeName>
                                    <Chain1>
                                        <Molecule>
                                            <GenBankId>1T03_H</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10090</SourceOrganismId>
                                    </Chain1>
                                    <Chain2>
                                        <Molecule>
                                            <GenBankId>1T03_L</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10090</SourceOrganismId>
                                    </Chain2>
                                </MultiChainMolecule>
                            </AssayedAntibodyObject>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>HIV-1 RT p51/p66 dimer/DNA</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>NP_789739.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>11676</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <ComplexedMolecule>
                                    <ComplexType>Protein conjugate</ComplexType>
                                    <PeptideModifications/>
                                    <SourceMolecule>
                                        <GenBankId>YP_001856242.1</GenBankId>
                                    </SourceMolecule>
                                    <MoleculeSourceOrganismId>11676</MoleculeSourceOrganismId>
                                </ComplexedMolecule>
                            </AntigenContainingObject>
                        </Antigen>
                        <ThreeDimensionalStructureOfComplex>
                            <ComplexPdbId>1N5Y</ComplexPdbId>
                            <AntibodyChain1PdbChain>H</AntibodyChain1PdbChain>
                            <AntibodyChain2PdbChain>L</AntibodyChain2PdbChain>
                            <AntigenChainPdbChain>B</AntigenChainPdbChain>
                            <ViewerFlag>Y</ViewerFlag>
                            <CuratedContacts>
                                <EpitopeResidues>B: ;</EpitopeResidues>
                                <AntibodyResiduesInteractingWithAntigen>H: ; L: ;</AntibodyResiduesInteractingWithAntigen>
                            </CuratedContacts>
                            <CalculatedContacts>
                                <EpitopeResidues>B: R199, Q222, K223, E224, P225, P226, F227, W229, M230</EpitopeResidues>
                                <AntibodyResiduesInteractingWithAntigen>H: S32, W54, W55, D56, D58, R60, I102, T103, S104, V105, S108; L: Y32, Y91, S92, K93, F94</AntibodyResiduesInteractingWithAntigen>
                                <ContactAreaForAntigen>689.4</ContactAreaForAntigen>
                                <ContactAreaForAntibody>606.6</ContactAreaForAntibody>
                            </CalculatedContacts>
                        </ThreeDimensionalStructureOfComplex>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

